Bioequivalence and Bioavailability Forum 15:57 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

What's the problem? [Regulatives / Guidelines]

posted by nobody - 2017-05-17 09:31  - Posting: # 17364
Views: 9,148

PS: No, I don't think that assay performance will do anything to intraindiv. CV of a drug product, as long as

- not practically all samples are around LLOQ
- effects are not random.

Did some sims in the old daysTM, effect of assay when validated according to current recommendations is negligible.

Especially for the "11% CV in 5 other trials, suddenly 40% in my trial" example there is no explanation remotely related to assay.

Kindest regards, nobody

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,606 posts in 3,959 threads, 1,208 registered users;
online 18 (1 registered, 17 guests [including 15 identified bots]).

EMEA. The European Medicines Evaluation Agency.
The drug regulatory agency of the European Union.
A statistician-free zone.    Stephen Senn

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed